Thursday 16 October, 2025
This population analysis characterises the pharmacokinetics of cetirizine in infants and children using data pooled from six clinical trials following…
Read moreposter
Pharmacokinetic mixed effects modelling of a new compound in rat – Combined analysis.
Thursday 16 October, 2025
Introduction and Objectives Several toxicokinetic (TK) and pharmacokinetic (PK) studies have been performed with a new drug composed of two…
Read moreCombined-PK-Analysis of a new compound exhibiting highly variable plasma profiles due to first pass metabolism
Thursday 16 October, 2025
INTRODUCTION AND OBJECTIVES The compound (S-X) is characterised by good absorption but a low bioavailability due to a saturable first-pass…
Read moreIvabradine and S18982 activities on heart rate: a population PK/PD analysis
Thursday 16 October, 2025
PDF of poster The ivabradine was developed for its heart rate decrease properties. The overall activity is related to both…
Read morePopulation PK/PD modeling of supine heart rate after oral administration of a new candidate antipsychotic drug
Thursday 16 October, 2025
PDF of poster Objectives: In the first clinical studies with a new candidate antipsychotic, supine heart rate (HR) increased, which…
Read moreModeling the occurrence of orthostasis using a longitudinal logistic regression model
Thursday 16 October, 2025
Introduction: A new drug candidate in development was associated with an increased risk to develop orthostasis at the start-up of…
Read moreModelling of the effect of carbamazepine on the pharmacokinetics of risperidone in psychotic patients of different phenotypes
Thursday 16 October, 2025
Introduction: Risperidone (RIS) is a well-known and widely used atypical antipsychotic drug, on the market for almost a decade now.RIS…
Read moreModeling the longitudinal concentration-response data after i.m. administration of Risperdal CONSTATM in psychotic patients of different phenotypes
Thursday 16 October, 2025
Introduction: A depot injectable formulation of Risperidone (RIS, Risperdal CONSTATM) for i.m. administration once every two weeks has been developed…
Read moreUse of Time-to-event analysis to qualify activity of Ivabradine durign exercise tolerance tests
Thursday 16 October, 2025
Ivabradine was developed for the treatment of angina pectoris. Its action combined to that of S 18982 (its active metabolite)…
Read moreGauss Hermite Quadrature in Population Parameters Estimation. Application to the Detection of Subpopulations
Thursday 16 October, 2025
Several methods have been proposed for estimating the different parameters entering the non-linear mixed effects models in population pharmacokinetics/pharmacodynamics. This…
Read more